Comparative medicine

Novel research leverages AI to identify dogs at higher risk for cancer

Retrieved on: 
Tuesday, March 26, 2024
B-cell lymphoma, Intelligence, Partnership, Risk, Research, DNA, Golden, Cancer, University, Mammal, Morris Animal Foundation, Veterinarian, Human, Dog, Lymphoma, Comparative medicine, Lyra, Cat, Blood, Animal, DLBCL, Ageing

Findings may help identify dogs at higher risk for DLBCL.

Key Points: 
  • Findings may help identify dogs at higher risk for DLBCL.
  • The team plans to provide pet owners and veterinarians with intervention strategies to help lower the risk in identified dogs.
  • Beyond its direct impact on dogs, this research effort could influence numerous research avenues in other mammals, including cats, endangered species and even humans, Modiano added.
  • The approach may also provide insights into aging, cancer risk and chronic conditions, extending the study's significance beyond companion dogs.

Cindy Buckmaster joins Turner Scientific, LLC

Retrieved on: 
Tuesday, August 2, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Veterinary, Sentinel, Sale, Brain, Center, Baylor University, Laboratory, Biomedical Research, Doctor of Philosophy, Temperature, Research, National Animal Interest Alliance, Behavior, Multimedia, Baylor College of Medicine, Organization, Outreach, Americans for Medical Progress, Biotechnology, Humidity, Science, Patient, Vibration, Texas Society of Architects, Cognition, Animal, Noise, Comparative medicine, Management, Pharmaceutical industry, Neuroscience

View the full release here: https://www.businesswire.com/news/home/20220802005429/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220802005429/en/
    Cindy Buckmaster, Ph.D., joins Turner Scientific as Chief Operating Officer of Facility Monitoring Services.
  • (Photo: Business Wire)
    Were thrilled to have Cindy join our team, said Turner Scientifics Chief Scientific Officer and founder, Jeremy Turner, PhD.
  • I am honored to represent Turner Scientific and believe strongly in their mission to drive more rigorous and reproducible science, said Dr. Buckmaster.
  • Lastly, Dr. Buckmaster will assist Turner Scientifics hearing research business in establishing its novel minipig model for preclinical auditory studies.

Odyssey Therapeutics Appoints Darryl Patrick, D.V.M., Ph.D., as Executive Vice President of Non-Clinical Development

Retrieved on: 
Tuesday, May 24, 2022
Sigma Xi, Inflammation, United, Diplomate of National Board, Chemistry, Anatomical pathology, Disease, Pharmacology, Toxicology, Vertex Pharmaceuticals, Pathology, American College, Chemical safety assessment, Coronavirus Scientific Advisory Board (Turkey), Multimedia, Patient, View, Antibody, University of Health Sciences, Veterinary medicine, Therapy, Pharmacokinetics, Merck, Technology, Comparative medicine, Key, Diagnosis, Biotechnology, Uniformed Services University of the Health Sciences, Uniformed services, Autoimmune disease, University, Iowa State University, Michigan State University, LinkedIn, Protein, Outline of health sciences, LLC, Cancer, Drug discovery, Indinavir, Merck & Co., Pharmaceutical industry, Management, EU, Science, Odyssey, Vertex

BOSTON, May 24, 2022 /PRNewswire/ -- Odyssey Therapeutics, Inc. , a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the appointment of Darryl Patrick, D.V.M., Ph.D., as Executive Vice President of Non-Clinical Development.

Key Points: 
  • BOSTON, May 24, 2022 /PRNewswire/ -- Odyssey Therapeutics, Inc. , a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the appointment of Darryl Patrick, D.V.M., Ph.D., as Executive Vice President of Non-Clinical Development.
  • "I'm excited to welcome Darryl to accelerate the development pathway for transformative medicines and provide hope for patients in need."
  • Previously, Dr. Patrick held leadership roles at Vertex as Vice President, Non-Clinical Development, and Vice President, Exploratory Development, where he oversaw development candidates from discovery to approval and led global efforts spanning toxicology, drug metabolism and pharmacokinetics, and clinical pharmacology.
  • "Odyssey has assembled an exceptional team and is positioned to be a leader in precision medicines for inflammation and cancer," said Darryl Patrick, D.V.M., Ph.D., about his new role as Executive Vice President, Non-Clinical Development at Odyssey Therapeutics.

DGAP-News: Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

Retrieved on: 
Monday, December 20, 2021
U.S. Securities and Exchange Commission, BID, Vital signs, MAD, Metabolism, Half-life, TH1, Hepatotoxicity, Clinical trial, SAD, Single, Inflammatory bowel disease, Private Securities Litigation Reform Act, Comparative medicine, Degenerative disease, Multiple sclerosis, Thymocyte, COVID-19, PK, Primary sclerosing cholangitis, Nature, T helper 17 cell, Annual report, SEC, Plasma, NEW, ET, DHODH, Safety, AUC, Patient, Cytokine, Ulcerative colitis, Crohn's disease, Drug development, Lymphocyte, Security (finance), Risk, Antibody, Part, Mouse, Psoriasis, Tmax, Pharmaceutical industry, Medical imaging, Vaccine, Cmax, Short course immune induction therapy, Webcast, IMU-935, Immunic, Inc., IMU-935, IMMUNIC, INC.

Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

Key Points: 
  • Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
    The issuer is solely responsible for the content of this announcement.
  • Moreover, single ascending doses of IMU-935 were found to be safe and well-tolerated and no maximum tolerated dose was reached.
  • These favorable results allowed a smooth transition to the MAD part of the trial using the new formulation.
  • Multiple ascending doses of IMU-935 were found to be safe and well-tolerated and no maximum tolerated dose was reached.

PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin Capsules

Retrieved on: 
Thursday, November 4, 2021
Pharmacodynamics, Aspirin, Florida College, Pharmacokinetics, University, Poster, Assistant, PD, Failure, Stomach, Comparative medicine, TCT, Private Securities Litigation Reform Act, NASDAQ, FDA, OBI Pharma, Inc., Risk, PLX, Marketing, Company, Patent, Pharma, Absorption, CEO, Platelet, Pain, API, Division, Intellectual property, GLOBE, Cardiology, Generic drug

SPARTA, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuardTM drug delivery platform that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORETM 325 mg and VAZALORETM 81 mg liquid-filled aspirin capsules (referred to together as “VAZALORE”), today announced the availability of additional scientific data that builds upon the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VAZALORE 81 mg and compared with enteric coated aspirin (EC-ASA).

Key Points: 
  • The Company, with its lead products VAZALORETM 325 mg and VAZALORETM 81 mg liquid-filled aspirin capsules (referred to together as VAZALORE), today announced the availability of additional scientific data that builds upon the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VAZALORE 81 mg and compared with enteric coated aspirin (EC-ASA).
  • PLx Pharma conducted a randomized, open-label, crossover study where preliminary results showed VAZALORE 81 mg provided fast and reliable absorption after a single dose.
  • We are excited that these findings provide additional clinical information about our FDA-approved VAZALORE liquid-filled aspirin capsules, beyond the first studies that supported approval of VAZALORE 81 mg and VAZALORE 325 mg, said Natasha Giordano, President and CEO of PLx Pharma.
  • VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses.